The Dynamics of Public Policy

The Dynamics of Public Policy

Theory and Evidence

New Horizons in Public Policy series

Adrian Kay

In The Dynamics of Public Policy, Adrian Kay sets out the crucial methodological, theoretical and empirical implications of two important trends in the social sciences: a frequently expressed ambition for analysis of ‘movies not stills’ and the regular observation that policy, politics and governance is becoming more complex.

Chapter 9: UK Pharmaceutical Policy

Adrian Kay

Subjects: politics and public policy, public policy


The tendency of doctors to overprescribe medicines because they do not bear the cost of the decision to prescribe, and the monopoly that pharmaceutical companies enjoy in the production of certain medicines under patent, are both long-standing justifications for pharmaceutical public policy to regulate the price of medicines (Bloom and Van Reenen, 1998). All OECD countries have some form of regulation of the pharmaceutical industry and mechanisms to control public expenditure on medicines. These policies have been under budgetary pressure in most countries since the 1980s due to the combination of an ageing population and technological development. NHS expenditure on prescription medicines increased by almost 10 per cent per annum during the 1990s (OHE, 2002). This fiscal pressure has produced a series of policy dynamics that exemplify how policy processes are as much about choosing between different reasons for action or different values, as they are about how to achieve particular values in isolation. This insight complements the point made in the theoretical section of the book: a dynamic perspective raises serious doubts about the instrumental, parametric version of rationality that exists in rational choice theory by challenging the notion of a straightforward policy ‘choice’. Public policy towards pharmaceuticals can be divided into those aimed at influencing the demand for medicines, chiefly to increase the sensitivity of GPs to the cost of medicines, and those aimed at regulating the supply side, the price paid for medicines by public authorities. In the UK, since the mid 1980s there have been a...

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information